About RDC

At Alfa Cytology, we offer radionuclide drug conjugates (RDC) development services powered by state-of-the-art RDC development and analysis platforms. These platforms are specifically designed to support our clients with end-to-end solutions, from early-stage discovery through to final product development. In addition, we offer comprehensive analytical testing, expert consulting, and customized services tailored to meet unique project requirements to help streamline and accelerate our partners' RDC development programs.

Technology

Overview of RDC

In the past decades, oncology is a research hotspot. With the discovery of targeted molecules, such as antibodies, small molecules, and peptides, precise treatment for cancer becomes possible. Nuclear medicine is widely used in the clinical treatment of cancer since the early 2000s. However, in general radiotherapy, the alpha-emitting radionuclides can cause great damage to the healthy parts of the patients. Notably, with targeted molecules combined with a radionuclide, the bifunctional RDC is capable to conduct diagnosis and treatment in one step, termed targeted alpha therapy (TAT).

Advantages of RDC

Combining two functional components, including targeting molecule and radionuclide, RDC brings together many advantages in clinical utilization.

Damage cancer cells precisely with minimal damage to healthy cells
Integrating therapeutic and diagnostic imaging roles in one
Flexibly designing to address different types of tumors

RDC Development Platforms

To support RDC development for worldwide clients, Alfa Cytology has established a professional RDC development platform to support high-quality RDC-related services.

By Conjugation Type

By Research Phase

By Application

We offer RDC development services from candidate screening to application in diagnostic imaging and targeted therapy.

Combining all of our excellent groups, Alfa Cytology can provide one-step and customized RDC-related services for worldwide clients with premium quality in a short time. If you are interested in our excellent RDC-related platform and technology, please contact us for more information.

Reference

Kitson, S. L. (2014). Application of Radionu-clides and Antibody-Drug Conjugates to Target Cancer. Cancer Stud Mol Med Open J, 1(1), 1-7.

For research use only.

Related Service

Related Application